FDA Approved: RETACRIT — Supplemental Application (Vifor (International) Inc.)

View source ↗

Summary

The FDA approved a supplemental application for RETACRIT (epoetin alfa-epbx) submitted by Vifor (International) Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Chemotherapy-induced Anemia
• Chronic Kidney Disease
• HIV Infection

Drugs mentioned

• RETACRIT (EPOETIN ALFA-EPBX)

Snippet

SUPPL AP for RETACRIT (EPOETIN ALFA-EPBX)